Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
PRNewswire - November 17, 2005
- Innovative Trial Design Offers Two Investigational Antiretrovirals in Combination
Tibotec Pharmaceuticals Ltd. announced today the opening of its pivotal phase III clinical trial program for its investigational non-nucleoside reverse transcriptase (NNRTI), TMC125. The program comprises two randomized, placebo-controlled trials in treatment-experienced HIV-1 infected adult patients with documented NNRTI resistance and at least 3 primary protease mutations. The two clinical trials of 600 patients each will be carried out in 18 countries.
In these studies, the background protease inhibitor (PI) will be Tibotec's investigational PI, TMC114. This pioneering trial design will be the first time that two new investigational antiretrovirals have been studied together in combination in heavily treatment experienced patients. The Antiviral Division of the U.S. Food and Drug Administration (FDA), the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) and the HIV patient community are supportive of this design.
Currently approved NNRTIs lose their antiviral activity in the presence of a single NNRTI mutation. TMC125 has shown activity in vitro against NNRTI-resistant virus. The first long-term clinical results of TMC125 in HIV-1 patients with NNRTI resistance will be presented as two late-breaker oral presentations at the European AIDS conference, 17-20th November in Dublin, Ireland. TMC125-C223 was a phase 2b dose-ranging, randomized, partially-blinded study in HIV-1 infected patients with substantial treatment experience and documented evidence of NNRTI resistance and 3 or more protease mutations. Despite the patients' NNRTI resistance, the viral load reduction in patients receiving TMC125 was significantly greater than in the active control at the 24-week primary endpoint. The mean change from baseline in viral load was -1.04, -1.18 and -0.19 log10 copies/ml in the TMC125 400 and 800 mg bid and active control groups, respectively
TMC125-C203 was a Phase II dose-escalation trial in which the primary objective was to assess the safety and tolerability of TMC125. The most common adverse events (AEs) were diarrhoea, headache, rash and nausea with the incidence of AEs not substantially different between TMC125 and placebo.
"We know that many people living with HIV/AIDS have run out of treatment options because of the growing problem of viral resistance. Preliminary data suggests TMC125 has the potential to be the first NNRTI active against these resistant strains," said Brian Woodfall, M.D., Global Medical Leader TMC125.
TMC125 has received Fast Track designation from the US Food and Drug Administration; such designation is conferred on drugs that are intended for the treatment of serious or life-threatening conditions.
Tibotec Pharmaceuticals Ltd.: Research & Development:
Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium.
Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and superior anti-infectives for diseases of high unmet medical need.
For further information, please visit: http://www.tibotec.com
SOURCE Tibotec Pharmaceuticals Ltd
051117
PR051137
Copyright © 2005 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .